Telix files 6-K: US$206M revenue; FY 2025 guidance upgraded

Q: What revenue figure is cited for Telix Pharmaceuticals (TLPPF)?

The announcement title cites US$206 million revenue.

Q: Did Telix update its FY 2025 guidance?

Yes. The title states FY 2025 guidance upgraded.

Q: Where can I find the full details referenced by TLPPF?

In Exhibit 99.1, the attached ASX announcement.

Q: When was the document signed and furnished?

The signature block shows October 14, 2025.

Q: What is the company associated with this 6-K?

Telix Pharmaceuticals Limited (TLPPF).

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited furnished a Form 6-K noting it filed an ASX announcement titled “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded.”

The exhibit (99.1) highlights reported revenue of US$206 million and an upgrade to FY 2025 guidance, as described in the announcement title. Further operational or financial details are contained in the attached exhibit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TLPPF report in its Form 6-K?

It furnished an ASX announcement titled “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded,” attached as Exhibit 99.1.

What revenue figure is cited for Telix Pharmaceuticals (TLPPF)?

The announcement title cites US$206 million revenue.

Did Telix update its FY 2025 guidance?

Yes. The title states FY 2025 guidance upgraded.

Where can I find the full details referenced by TLPPF?

In Exhibit 99.1, the attached ASX announcement.

When was the document signed and furnished?

The signature block shows October 14, 2025.

What is the company associated with this 6-K?

Telix Pharmaceuticals Limited (TLPPF).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/14/2025 - 08:36 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 14, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded,” which is attached to this Form 6-K as Exhibit 99.1.

99.1	Press release – October 14, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Telix Pharmaceuticals Limited

Date: October 14, 2025	By:	/s/ Genevieve Ryan
		Name: Genevieve Ryan
		Title: Company Secretary

Source: View Original Filing on SEC EDGAR